Sandoz announced today that the FDA has accepted its Biologics License Application (BLA) for a proposed rituximab biosimilar. The drug is referenced on Rituxan, which is approved to treat blood cancers and immunological diseases.
Sandoz announced today that the FDA has accepted its Biologics License Application (BLA) for a proposed rituximab biosimilar. The drug is referenced on Rituxan, which is approved to treat blood cancers and immunological diseases.
The BLA’s data package includes analytical, preclinical, and clinical data, including a pharmacokinetic and pharmacokinetic trial of the proposed drug in the ASSIST-RA rheumatoid arthritis trial phase 3 confirmatory safety and efficacy data from the ASSIST-FL follicular lymphoma study.
Sandoz says that it hopes its drug will, if approved, help reduce the high cost of biologic treatment. “The cost of treating cancer in the [United States] is a major concern for many patients and their families as well as for the healthcare system,” said Mark Levick, MD, PhD, global head of biopharmaceuticals development for Sandoz. “With the FDA acceptance of our regulatory submission for proposed biosimilar rituximab, we plan to…[free] up resources for and [support] patient access in other areas of cancer care including innovative therapies.”
In June, Sandoz received approval from the European Commission to market its rituximab biosimilar in Europe. Under the name Rixathon, Sandoz’s product is approved to treat all indications of the reference rituximab. Sandoz called the product 1 of 5 major launches the company has planned for the coming 4 years.
While the reference rituximab already faces competition from biosimilars in Europe, the global market for the drug has continued to grow; the branded drug earned $8.58 billion for Genentech in 2016, an increase of 2.7% from its 2015 sales.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer
March 12th 2024A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.